A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

NCT02203032 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

872

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Ustekinumab
DRUG: Guselkumab
DRUG: Placebo for ustekinumab
DRUG: Placebo for guselkumab

Sponsor

Janssen Research & Development, LLC